drugset / Trial / NCT05345613

Tranexamic Acid During Colonic Endoscopic Resection Procedures

NCT05345613 ↗

Phase 4 Recruiting 200 enrolled Assaf-Harofeh Medical Center
RandomizedParallel-groupSingle-blindPrevention

Summary

Colonoscopy with polypectomy reduces the incidence and mortality associated with colon cancer. However, polypectomy is associated with adverse events such as bleeding. Tranexamic acid (TXA) is a synthetic derivative of lysine that exerts antifibrinolytic effects and may prevent bleeding. The investigators aim to evaluate the effect of local TXA on preventing intraprocedural and postprocedural bleeding in patients undergoing endoscopic mucosal resection (EMR) of large colon polyps.

Timeline

Start
2022-05-01
Primary completion
2026-09-01
Completion
2026-10-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Epinephrine Other / unclassified — Other
Subject Tranexamic Acid Small molecule — Other

Indications